2 The most recent trials successfully demonstrated that a combination of drugs can treat up to 90% of people with Cystic Fibrosis by addressing the underlying cause of their disease. There are over 80,000 people living with Cystic Fibrosis globally, including 10,500 in the UK - accounting for 9,500 hospital admissions and over 100,000 bed days per year.
#PJET VECTOR IN SERIAL CLONER TRIAL#
Extensive clinical trial experience coupled with a Clinical Trial Network infrastructure established by Queen’s and the Belfast Health and Social Care Trust, resulted in Queen’s playing a pivotal role in a drug development programme working alongside Vertex Pharmaceuticals to deliver trials for single, double and triple therapies in Cystic Fibrosis. This work included the development of clinical trial protocols, and inclusion of key outcome measures such as lung function (FEV1), pulmonary exacerbation rate, and Quality of Life (QoL) tools for use in clinical trials of new therapeutics. during the last decade, Queen’s University Belfast has been at the forefront of major advancements in drugs targeting the underlying genetic deficit. Queen’s University’s Cystic Fibrosis research team is recognised as world leading, having worked for over 12 years supporting the development of drugs that improve the function of CTFR. The mutations can lead to the build-up of thick mucus in the lungs, digestive tract and other parts of the body causing persistent chest infections, resulting in lung damage and an early death. The condition is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which is responsible for the regulation of salt and water levels in the body. There are over 80,000 people living with Cystic Fibrosis globally, including 10,500 in the UK accounting for 9,500 hospital admissions and over 100,000 bed days per year. Cystic Fibrosis is a progressive, life-limiting genetic disease that causes severe respiratory and digestive problems as well as other complications such as infections and diabetes. Researchers from Queen’s have transformed the lives of people with Cystic Fibrosis by leading on the clinical development of treatments that address the underlying genetic disorder. This unique Open Innovation model allows research to translate to industry in an agile way, ensuring demonstrable technology is in the hands of end users quickly. Its unique membership model has seen the development of longstanding advisory and industrial collaborations with global partners including Altera, Allstate, BAE Systems, Cisco, Citi, Direct Line Group, First Derivatives, IBM, Infosys, Intel, McAfee, Roke, Seagate and Thales. Industry engagement is at the heart of CSIT. A safe and secure cyberspace is fundamental to making the UK the safest place in the world to live and work online. Cyber security challenges have grown exponentially in the last decade. CSIT's mission is to produce significant high-quality impactful research in four key research areas: - Secure connected services - Networked security systems - Industrial control systems - Security intelligence CSIT couples major research breakthroughs in the field of secure information technologies with a unique model of innovation and commercialisation to drive economic and societal impact. CSIT plays a key role in Northern Ireland’s cybersecurity ecosystem through the development of incubator programmes, start-ups and attracting foreign direct investment which had led to the creation of approximately 1600 jobs in this sector. The Centre for Secure Information Technologies (CSIT) is a national cybersecurity research institute based at Queen’s emphasising research excellence combined with a unique model for, and focus on, commercialisation and innovation.
0 kommentar(er)
